Skip to main content

Table 1 Baseline characteristics of the randomized controlled trial population, according to treatment arm.

From: Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major

 

Combined

Deferoxamine

p-value

Number of patients

32

33

-

Age (years)

28.8 ± 4.2

28.7 ± 5.3

0.9

Gender (male)

14 (44%)

13 (39%)

0.5

Body surface area

1.53 ± 0.15

1.56 ± 0.16

0.5

Heart rate

78 ± 10

81 ± 16

0.3

Deferoxamine dose (mg/kg/day)

40.6 ± 13.2 (5 days/week)

a

1.0

CMR measures

   

Myocardial T2*

11.7 (0.08)

12.4 (0.11)

0.3

Liver T2*

4.9 (0.52)

4.2 (0.62)

0.5

RVEDV (mL)

129.5 ± 30.8

131.8 ± 34.4

0.8

RVESV (ml)

52.5 ± 17.5

52.3 ± 18.5

1.0

RVEF (%)

60.2 ± 7.2

61.0 ± 7.1

0.7

Echo measures

   

PAP (mmHg)

22.3 ± 5.0

20.9 ± 5.4

0.4

Blood measures

   

Transfusional red blood cell input (mL/kg/year)

133.4 ± 34.9

130.2 ± 38.6

0.7

Haemoglobin (g/L)

106 ± 9.6

102 ± 9.5

0.1

Hepatitis C positive

23 (72%)

26 (79%)

0.4

Serum ferritin (μg/L)

1574 (11)

1379 (10)

0.5

BNP (pmol/L)

13.6 (5.6, 30.1)

15.2 (7.3, 26.2)

0.7

Creatinine (mg/dL)

0.77 ± 0.21

0.74 ± 0.23

0.6

Cardiac medication

   

Any

5 (16%)

8 (24%)

0.4

Digoxin

3 (9%)

4 (12%)

0.7

ACEi/ARB

5 (16%)

8 (24%)

0.4

Diuretics

3 (9%)

5 (15%)

0.5

  1. Values are presented as n (%), mean ± SD, geometric mean (coefficient of variation), or as median (25th - 75th percentile). RV = right ventricular; EDV = end-diastolic volume; ESV = end-systolic volume; PAP = pulmonary artery systolic pressure; BNP = B-type natriuretic peptide. ACEi = angiotensin-converting enzyme inhibitors; ARB = angiotensin II receptor blockers.